Influenza Activity — United States and Worldwide, May 19–September 28, 2019, and Composition of the 2020 Southern Hemisphere Influenza Vaccine

Scott Epperson, DVM; C. Todd Davis, PhD; Lynnette Brammer, MPH; Anwar Isa Abd Elal; Noreen Ajayi, MPH; John Barnes, PhD; Alicia P. Budd, MPH; Erin Burns, MA; Peter Daly, MPH; Vivien G. Dugan, PhD; Alicia M. Fry, MD; Yunho Jang, PhD; Sara Jo Johnson, MPH; Krista Kniss, MPH; Rebecca Kondor, PhD; Lisa A. Grohskopf, MD; Larisa Gubareva, PhD; Angiezel Merced-Morales, MPH; Wendy Sessions, MPH; James Stevens, PhD; David E. Wentworth, PhD; Xiyan Xu, MD; Daniel Jernigan, MD


Morbidity and Mortality Weekly Report. 2019;68(40):880-884. 

In This Article

Composition of the 2020 Southern Hemisphere Influenza Vaccine

WHO recommendations for influenza vaccine composition for the Southern Hemisphere 2020 season were made at the WHO Consultation and Information Meeting on the Composition of Influenza Virus Vaccines held September 23–27, 2019, in Geneva, Switzerland.†† The recommended components for the 2020 Southern Hemisphere egg-based influenza trivalent vaccines are an A/Brisbane/02/2018 (H1N1)pdm09-like virus, an A/South Australia/34/2019 (H3N2)-like virus, and a B/Washington/02/2019-like virus (B/Victoria lineage). For egg-based quadrivalent vaccines, an additional component, B/Phuket/3073/2013-like virus (B/Yamagata lineage), is recommended. It was recommended that the A(H3N2) component of non–egg-based vaccines be a cell-propagated A/Iowa/60/2018-like virus.